NewsEvents

ADx presents at ADPD results on VAMP2, a new synaptic biomarker showing significant changes in very early pre-clinical disease state.

By 2 April 2020No Comments

ADx presents at ADPD results on VAMP2, a new synaptic biomarker showing significant changes in very early pre-clinical disease state.

While the classical fluid markers, tau and amyloid, accord well with pathological changes in the brain, there is an increased interest in synaptic biomarkers as they may have additional diagnostic value in the AD continuum. Several studies demonstrate that neurogranin is specific for AD and has added value compared to the classical fluid markers, while synaptic neuronal pentraxin-2 seems to be the best biochemical correlate of cognitive decline in AD. In collaboration with Dr A. LleĆ³ and Dr. O. Belbin (Sant Pau Memory Unit, Barcelona) ADx will present a new CSF synaptic biomarker, VAMP2, at ADPD 2020. Using a highly sensitive immunoassay we confirm the original observation of VAMP2 CSF changes prior to a CSF tau increase in early preclinical AD stages.

We kindly invite you to have a look at our virtual scientific session in symposium 34 on Saturday, April 4. Do not hesitate to get in touch for more information!

The AAT-AD/PD 2020 participants can follow this link directly to the session.

AAT-AD/PD 2020